AP NEWS

Growth Hormone Antagonist - Pipeline Insight 2018 - ResearchAndMarkets.com

December 21, 2018

DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The “Growth Hormone Antagonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Growth Hormone Antagonist - Pipeline Insight, 2018′ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Growth Hormone Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Growth Hormone Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Growth Hormone Antagonist - Overview

3. Pipeline Therapeutics4. Comparative Analysis

5. Growth Hormone Antagonist Pipeline Products in Clinical Stages

6. Growth Hormone Antagonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies Mentioned

Biscayne Pharmaceuticals Italfarmaco Ipsen Chiasma Novartis Peptron GlaxoSmithKline

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fkdxq4/growth_hormone?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005194/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/21/2018 06:43 AM/DISC: 12/21/2018 06:43 AM

http://www.businesswire.com/news/home/20181221005194/en

AP RADIO
Update hourly